FIRALIS S.A. logo

FIRALIS S.A.

Innovative biomarker solutions for improved diagnostics, enhancing patient outcomes and optimizing healthcare costs.

28 employees · est. 2008 · France

VS
SENSEERA logo

SENSEERA

Empowering diagnostics and drug development with AI-driven chromatin liquid biopsy

20 employees · est. 2020 · Jerusalem, Israel

FIRALIS S.A. is the older company (2008 vs 2020).

Side-by-Side Comparison

FIRALIS S.A. SENSEERA
Founded
2008 older 2020
Headquarters
France Jerusalem, Israel
Employees
28 20
Industry
Biotechnology, Health Care, Industrial Health Care
Funding Stage
Series B Not tracked yet
Total Funding
$1.93M Not tracked yet
Funding Rounds
2 Not tracked yet
Services
Not tracked yet AI-driven chromatin liquid biopsy, Diagnostic platform for disease monitoring, Non-invasive gene expression analysis, Biomarker generation for treatment monitoring
Target Customers
Not tracked yet Pharmaceutical companies, Biotechnology firms, Clinical researchers, Healthcare providers, Diagnostic laboratories
Taxonomy
Biomarker Development, Diagnostic Tools, Biomarker R&D, Drug Safety, Personalized Medicine, Biomarker-related CRO Services, Proteomics, Genomics, Transcriptomics, Flow Cytometry, Assay Development, Biobanking, Regulatory Qualification, Precision Medicine, Alzheimer's AI-driven Diagnostics, Chromatin Liquid Biopsy, Biomarker Discovery, Genomic Expression Maps, Cell-free DNA Analysis, Tissue-agnostic MRD Detection, Therapy Response Monitoring, Dose Optimization, Disease Subtyping, Precision Medicine, Drug Development Collaboration, Quantitative Gene Expression, Regulatory Data, Sensitivity And Specificity, Biotech Partnerships
Website
firalis.com senseerahealth.com
FIRALIS S.A. logo

About FIRALIS S.A.

FIRALIS S.A. is a leading biotechnology company based in Basel, Switzerland, specializing in innovative biomarker solutions for enhanced diagnostics, improved patient outcomes, and optimized healthcare costs. Since its establishment in 2008, the company has been at the forefront of biomarker (BM) di...

SENSEERA logo

About SENSEERA

SENSEERA is a promising player in the Health Care sector, founded in 2020 and based in Israel. The company is pioneering advancements in diagnostics and drug development with its AI-driven chromatin liquid biopsy technology. The foundation of SENSEERA's innovation is its patented GEM (Genomic Expre...

We will tell you when either one moves

BounceWatch watches FIRALIS S.A. and SENSEERA for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at FIRALIS S.A. and SENSEERA — by email.

Frequently Asked Questions

FIRALIS S.A. — Innovative biomarker solutions for improved diagnostics, enhancing patient outcomes and optimizing healthcare costs.. SENSEERA — Empowering diagnostics and drug development with AI-driven chromatin liquid biopsy. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
FIRALIS S.A. has raised $1.93M while SENSEERA has raised undisclosed funding.
FIRALIS S.A. and SENSEERA operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare FIRALIS S.A. with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at FIRALIS S.A. on 7 Jun 2025, and SENSEERA on 5 Apr 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy